CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2023; 7: (11) ; 1-5 ; DOI: 10.12208/j.ijcr.20231340.

Advances in immune checkpoint inhibitor-based therapeutic studies for hepatocellular carcinoma
基于免疫检查点抑制剂的肝细胞癌治疗研究进展

作者: 裴捷, 王百林 *

暨南大学附属广州红十字会医院 广东广州

*通讯作者: 王百林,单位:暨南大学附属广州红十字会医院 广东广州;

发布时间: 2023-11-21 总浏览量: 367

摘要

肝细胞癌(hepatocellular carcinoma,HCC)是全球癌症相关死亡的第四大主要原因,总体预后较差,因为大多数病例是在晚期诊断的,无法进行治愈性治疗。但随着免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的出现,显著提高了晚期HCC的治疗效果;然而,它们的反应率仍然不令人满意,部分原因是原发性或获得性耐药。为了克服这一局限性,因此衍生出ICIs与其他多种疗法(如分子靶向治疗、局部治疗、化疗)的联合治疗。基于此,本文对HCC的ICIs治疗以及联合治疗的临床研究进展进行综述。

关键词: 肝细胞癌;免疫检查点抑制剂;联合治疗

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths globally, with an overall poor prognosis, as most cases are diagnosed at an advanced stage, precluding curative treatment. However, with the advent of immune checkpoint inhibitors (ICIs), the therapeutic efficacy of advanced HCC has significantly improved; however, their response rates remain unsatisfactory, partly due to primary or acquired resistance. To overcome this limitation, combination therapy of ICIs with various other therapies (molecularly targeted therapy, topical therapy, chemotherapy) has therefore been derived. Based on this, this article reviews the progress of clinical studies on the treatment of HCC with ICIs and combination therapy.

Key words: Hepatocellular carcinoma; immune checkpoint inhibitors; combination therapy

参考文献 References

[1] Chen S, Cao Q, Wen W, et al. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities[J]. Cancer Letters, 2019, 460: 1-9.

[2] Cheng A-L, Hsu C, Chan S L, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma[J]. Journal of Hepatology, 2020, 72(2): 307-319.

[3] Wei S C, Duffy C R, Allison J P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy[J]. Cancer Discovery, 2018, 8(9): 1069-1086.

[4] Butte M J, Keir M E, Phamduy T B, et al. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses[J]. Immunity, 2007, 27(1): 111-122.

[5] El-Khoueiry A B, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. The Lancet, 2017, 389(10088): 2492-2502.

[6] Yau T, Park J W, Finn R S, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Annals of Oncology, 2019, 30: v874-v875.

[7] Zhu A X, Finn R S, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. The Lancet Oncology, 2018, 19(7): 940-952.

[8] Sangro B, Gomez-Martin C, De La Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. Journal of Hepatology, 2013, 59(1): 81-88.

[9] Fife B T, Bluestone J A. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways[J]. Immunological Reviews, 2008, 224(1): 166-182.

[10] Kaseb A O, Hasanov E, Cao H S T, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. The Lancet Gastroenterology & Hepatology, 2022, 7(3): 208-218.

[11] Kelley R K, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study[J]. Journal of Clinical Oncology, 2021, 39(27): 2991-3001.

[12] Wolf Y, Anderson A C, Kuchroo V K. TIM3 comes of age as an inhibitory receptor[J]. Nature Reviews Immunology, 2020, 20(3): 173-185.

[13] Lichtenegger F S, Rothe M, Schnorfeil F M, et al. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells[J]. Frontiers in Immunology, 2018, 9: 385.

[14] Lee M S, Ryoo B-Y, Hsu C-H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study[J]. The Lancet Oncology, 2020, 21(6): 808-820.

[15] Finn R S, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. New England Journal of Medicine, 2020, 382(20): 1894-1905.

[16] Finn R S, Ikeda M, Zhu A X, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma[J]. Journal of Clinical Oncology, 2020, 38(26): 2960-2970.

[17] Li L, Wu P-S, Liang X-M, et al. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study[J]. Journal of Gastroenterology, 2023, 58(10): 1043-1054.

[18] Xu J, Zhang Y, Jia R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study[J]. Clinical Cancer Research, 2019, 25(2): 515-523.

[19] Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial[J]. Clinical Cancer Research, 2021, 27(4): 1003-1011.

[20] Qin S, Bai Y, Lim H Y, et al. Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J]. Journal of Clinical Oncology, 2013, 31(28): 3501-3508.

[21] Li H, Qin S, Liu Y, et al. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study[J]. Drug Design, Development and Therapy, 2021, Volume 15: 1873-1882.

[22] El Dika I, Khalil D N, Abou‐Alfa G K. Immune checkpoint inhibitors for hepatocellular carcinoma[J]. Cancer, 2019, 125(19): 3312-3319.

[23] Marinelli B, Kim E, D'Alessio A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study[J]. J Immunother Cancer. 2022, 10(6):e004205.

[24] Pan X, Wu S-J, Tang Y, et al. Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience[J]. Journal of Hepatocellular Carcinoma, 2023, Volume 10: 883-892.

[25] Chiang C L, Chiu K W H, Chan K S K, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial[J]. The Lancet Gastroenterology & Hepatology, 2023, 8(2): 169-178.

[26] Li J-X, Su T-S, Gong W-F, et al. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial[J]. Hepatology International, 2022, 16(5): 1179-1187.

[27] Duffy A G, Ulahannan S V, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. Journal of Hepatology, 2017, 66(3): 545-551.

[28] Lyu N, Kong Y, Li X, et al. Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study[J]. Frontiers in Oncology, 2020, 10: 580241.

引用本文

裴捷, 王百林, 基于免疫检查点抑制剂的肝细胞癌治疗研究进展[J]. 国际临床研究杂志, 2023; 7: (11) : 1-5.